Daily Judi: Friday, January 6, 2023
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Researchers based at the University of Wisconsin–Madison have developed a way to grow cells resembling the retina, which may lead toward clinical trials for degenerative eye disorders. (Ophthalmology Times)
The United Kingdom has partnered with BioNTech for clinical trial patient access to BioNTech's mRNA-based cancer immunotherapies. (Pharmaphorum)
A new study published in Oncogene, identified that targeting a variant of the RAC1 protein, RAC1B, may improve breast cancer treatment. (The University of Manchester)
Our Culture
“I’ve been at the company over seven years, and it’s been really cool to watch the company grow and continue to increase how we help our clients. One of the many things I like about my job is that it’s not always the same thing every day, because each client is unique. It makes every day interesting.
Judi is a platform. It’s an adjudication tool, but it’s also more. It’s a whole collaborative workflow process tool. It works with DSMB, Eligibility, anything.”
–Stephen, Lead Engineer
About Judi
Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
